PI4KIIIBETA inhibiteur ; BF738735 1 pc x 10

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Reversible: yes

Primary TargetPI4KIII&beta

Cell permeable: yes

General description

A cell-permeable imidazo-pyrazine based compound that acts as a potent and reversible inhibitor of PI4KIIIβ (IC₅₀ = 5.7 nM). Displays excellent selectivity over PI4KIIIα (IC₅₀ = 1.7 µM) and several other lipid kinases (IC₅₀ >10 µM). Shown to dose-dependently decrease PI4P levels, reduce oxysterol-binding protein (OSBP) localization to replication organelles (ROs) and inhibit cholesterol shuttling to ROs (at 1 µM in BGM and HeLaR19 cells transfected with CVB3) at multiplicity of infection (MOI). Exhibits uniformly potent and broad spectrum antienteroviral activity across a wide range of species (EC₅₀ = 4-31 nM) and is inactive against RNA, DNA, and retroviruses.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Strating, J.R.P.M., et al. 2015. Cell Reports.10, 600.MacLeod, A.M., et al. 2013. ACS Med. Chem. Lett.4, 585.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)